All In Biotech

Drug Trial Radar · NCT04158648

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors

A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Emicizumab in Patients With Mild or Moderate Hemophilia A Without FVIII Inhibitors

Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

73

Actual

Start

Feb 10, 2020

Primary completion

Oct 30, 2021

Study completion Dec 19, 2025

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Nov 12, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, single-arm study designed to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of emicizumab in participants with mild or moderate hemophilia A without inhibitors against factor VIII (FVIII).

Conditions

  • Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor
  • Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor
  • Hemophilia A

Interventions

  • EmicizumabDrug

    Four loading doses of emicizumab 3 milligrams per kilogram of body weight (mg/kg) will be administered subcutaneously (SC) once a week (QW) for 4 weeks followed by participant's preference of one of the three following maintenance SC dose regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Model-Based Annualized Bleed Rate for Treated BleedsTime frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
  2. Mean Calculated ABR for Treated BleedsTime frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
  3. Median Calculated ABR for Treated BleedsTime frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)

Locations

22 sites in 10 countries. Site status is shown where the registry gives one.

  • Childrens Hospital LA

    Los Angeles, California

  • Hemophilia of Georgia Center for Bleeding & Clotting Disorders

    Atlanta, Georgia

  • Indiana Hemophilia & Thrombosis center

    Indianapolis, Indiana

  • University of Michigan, C.S. Mott Children's Hospital

    Ann Arbor, Michigan

  • Washington Institute for Coagulation

    Seattle, Washington

  • Cliniques Universitaires St-Luc

    Brussels, Belgium

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • Kaye Edmonton Clinic

    Edmonton, Alberta, Canada

  • Eastern Health - General Hospital

    St. John's, Newfoundland and Labrador, Canada

  • Hopital Cardio-vasculaire Louis Pradel

    Bron, France

  • CH de Bicetre

    Le Kremlin-Bicêtre, France

  • Groupe Hospitalier Necker Enfants Malades

    Paris, France

  • Universitätsklinikum Bonn

    Bonn, Germany

  • Klinikum der Universität München, Campus Innenstadt

    München, Germany

  • Amsterdam UMC Location AMC

    Amsterdam, Netherlands

  • Instytut Hematologii i Transfuzjologii

    Warsaw, Poland

  • Charlotte Maxeke Johannesburg Hospital

    Johannesburg, South Africa

  • Hospital Universitario la Paz

    Madrid, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

  • Cardiff and Vale NHS Trust

    Cardiff, United Kingdom

  • Royal Free Hospital

    London, United Kingdom

  • Great Ormond street Hospital for Children NHS Foundation Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.